ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

P134

A development code. Also written as “P134 cell injection”.

Its studies are mostly in Glioblastoma, led by China Resources Pharmaceutical Group.

Furthest: phase 2, since Nov 27, 20251 company-led study, 1 open or runningNext primary completion: Feb 29, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
China Resources Pharmaceutical Group11 open or runningphase 2since Nov 27, 2025Nov 27, 2025Feb 29, 2028phase 2 · NCT07318818

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 27, 2025First study: phase 2 study in Recurrent Glioblastoma IDH WildtypeFirst studyNCT07318818 · 26 planned · China

Ahead

  1. Feb 29, 2028Primary completion: phase 2 study in Recurrent Glioblastoma IDH WildtypeNCT07318818

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07318818Recurrent Glioblastoma IDH Wildtype · China2RecruitingFeb 29, 202826

How it is read

Names in the registry

  • “P134 cell injection”, 1 entry

Codes read as this program: P134.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.